LOUISVILLE, Ky., July 6, 2023 (Newswire.com)
-
HSG Advisors, a national healthcare consulting firm, received a top 20 ranking in Modern Healthcare's 2023 Management Consulting Firms Survey results. The firms were ranked by self-reported total net healthcare revenue for 2022. In addition to quantitative metrics, the annual survey gathered industry insights on trends, challenges, and best practices from responding firms.
"HSG Advisors has grown rapidly since its founding in 1999, and we're delighted to be recognized as one of the foremost healthcare consultancies in the nation," says Travis Ansel, CEO of HSG Advisors. "We appreciate the value Modern Healthcare provides to our industry as a premier source of news and information for healthcare executives."
The survey asked companies about the state of the healthcare sector over the past year and what they foresee for the industry in the future. Notably, respondents were asked to rank which consulting type is growing the most quickly, and data analytics received the highest number of responses, at nearly 20%. This industry response is on par with HSG Advisors' own growth trajectory; its Claims Data Analytics capabilities are among its most in-demand consulting services. In the survey, data analytics outranked operational improvement, margin improvement, digital transformation, and merger and acquisition consulting.
HSG Advisors specializes in employed physician networks, providing consulting on physician strategy, leadership, and compensation, as well as network integrity and healthcare system performance. The number of employed physicians surpassed the number of physicians with their own practices in 2018, and then the pandemic significantly accelerated this trend as healthcare mergers and acquisitions and physician buyouts rose 56% from 2020 according to a study issued by the Physicians Advocacy Institute in 2021. HSG Advisors has been uniquely positioned to guide employed physicians and healthcare leaders through this pivotal time, resulting in strong year-over-year revenue growth.
About HSG Advisors
HSG Advisors is a national healthcare consulting firm headquartered in Louisville, Kentucky. The practice empowers leaders to build differentiated health system strategies and high-performing employed physician networks by pairing data intelligence with experienced advice. The firm's comprehensive approach to leveraging market facts to inform healthcare strategies allows leaders to understand opportunities and deliver the right care to their communities. For more information about HSG, visit www.HSGAdvisors.com, LinkedIn, email info@hsgadvisors.com, or call (502) 814-1180.
Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating the potential efficacy of their proprietary cannabis-inspired mixtures today at the Canna Pharma 2022 Conference in San Diego, California. Dr. Small-Howard explains Gb Sciences' novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled "Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models." Gb Sciences' case studies include scientific evidence demonstrating the potential efficacy of their cannabinoid-based therapeutic mixtures designed to treat Parkinson's disease, chronic pain, or inflammation using their novel minimal essential mixture approach.
"Medicinal cannabis has shown great promise for the symptomatic treatment of many serious human disorders, but concerns around safety, consistency, legality, psychoactivity, and non-standardized routes of delivery, such as smoking and vaping, have slowed the adoption of the use of medical cannabis within traditional, physician-guided patient treatment programs. To address these challenges, we hypothesized that within Cannabis plant extracts, there would be a minimal essential mixture of compounds that preserves whole plant benefits, but with the manufacturing, quality control, and regulatory benefits of single ingredient therapies," said Dr. Andrea Small-Howard.
Minimal essential mixtures (MEM) is a term Gb Sciences has coined from their proprietary research after deeming that a simplified mixture represented a happy medium between whole plant medicines and single ingredient drugs. Minimum Essential Mixtures are designed to retain increased therapeutic effectiveness from molecular synergies within the original plant extracts, but with the manufacturing efficiencies, quality assurances, and regulatory advantages of single ingredient drugs. Gb Sciences' disease-specific MEM are produced for clinical evaluation using synthetic homologs of cannabis-based ingredients incorporated into sophisticated oral delivery modalities including Oral Dissolving Tablets (ODT), Oral Thin Films (OTF), time-released oral nanoparticles, and gel capsules to increase the stability, bioavailability, and ease-of-use of these ingredients relative to the non-standardized delivery methods used for Cannabis plant extracts.
Gb Sciences was recently published in Pharma's Almanac discussing the strategy behind their plant-inspired minimum essential mixtures, which provides context for the case studies being presented today.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
